Literature DB >> 12496277

Identification of gene-selective modulators of the bile acid receptor FXR.

Isabelle Dussault1, Rick Beard, Min Lin, Kevin Hollister, Jasmine Chen, Jia-Hao Xiao, Rosh Chandraratna, Barry M Forman.   

Abstract

BAR is a nuclear bile acid receptor (BAR) (FXR) receptor that regulates gene networks involved in cholesterol and bile acid homeostasis. We have identified two classes of synthetic compounds that differentially modulate BAR activity. The first class activates BAR target genes in the predicted fashion and is 25-fold more potent than endogenous bile acids. The second class, represented by AGN34, antagonizes BAR in transient reporter assays. Surprisingly, this compound acts in a gene-selective manner in vivo: it is an agonist on CYP7A1, an antagonist on IBABP, and is neutral on SHP. These findings indicate that synthetic BAR modulators can be developed to regulate transcription in a gene-specific fashion. Given the ability of BAR to regulate several lipid homeostatic pathways, the identification of gene-selective BAR modulators have important implications for the development of improved cholesterol lowering agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12496277     DOI: 10.1074/jbc.M209863200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.

Authors:  Zhongsheng Peng; Jiayan Chen; Cinthia B Drachenberg; Jean-Pierre Raufman; Guofeng Xie
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

Review 2.  FXR signaling in the enterohepatic system.

Authors:  Tsutomu Matsubara; Fei Li; Frank J Gonzalez
Journal:  Mol Cell Endocrinol       Date:  2012-05-17       Impact factor: 4.102

3.  Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice.

Authors:  Wenling Chen; Guoxen Chen; Daphne L Head; David J Mangelsdorf; David W Russell
Journal:  Cell Metab       Date:  2007-01       Impact factor: 27.287

4.  Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.

Authors:  Donna D Yu; Wenwei Lin; Barry M Forman; Taosheng Chen
Journal:  Bioorg Med Chem       Date:  2014-04-16       Impact factor: 3.641

Review 5.  The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism.

Authors:  Folkert Kuipers; Thierry Claudel; Ekkehard Sturm; Bart Staels
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

6.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

7.  Ligand-binding domain of farnesoid X receptor (FXR) had the highest sensitivity and activity among FXR variants in a fluorescence-based assay.

Authors:  Kyung-Hyun Cho; Ji-Young Park; Jang-Il Han; Tae-Sook Jeong
Journal:  Lipids       Date:  2003-11       Impact factor: 1.880

8.  Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.

Authors:  Donna D Yu; Wenwei Lin; Taosheng Chen; Barry M Forman
Journal:  Bioorg Med Chem       Date:  2013-05-07       Impact factor: 3.641

9.  The nuclear bile acid receptor FXR is activated by PGC-1alpha in a ligand-dependent manner.

Authors:  Eiko Kanaya; Takuma Shiraki; Hisato Jingami
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

Review 10.  Endocrine functions of bile acids.

Authors:  Sander M Houten; Mitsuhiro Watanabe; Johan Auwerx
Journal:  EMBO J       Date:  2006-03-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.